Diagnostic Microbiology & Infectious Disease
Volume 65, Issue 4 , Pages 404-413 , December 2009

Zyvox® Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008

  • Ronald N. Jones

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA
    • Tufts University School of Medicine, Boston, MA 02111, USA
    • Corresponding Author InformationCorresponding author. JMI Laboratories, North Liberty, IA 52317, USA. Tel.: +1-319-665-3370; fax: +1-319-665-3371.
    • ,
  • James E. Ross

      Affiliations

    • JMI Laboratories, North Liberty, IA 52317, USA
    • ,
  • Jan M. Bell

      Affiliations

    • Women's and Children's Hospital, North Adelaide, Australia
    • ,
  • Uchino Utsuki

      Affiliations

    • Toho University Sakura Medical Center, Chiba, Japan
    • ,
  • Ikeda Fumiaki

      Affiliations

    • Toho University Sakura Medical Center, Chiba, Japan
    • ,
  • Intetsu Kobayashi

      Affiliations

    • Mitsubishi Kagaku Bio Clinical Akita Laboratory, Tokyo, Japan
    • ,
  • John D. Turnidge

      Affiliations

    • Women's and Children's Hospital, North Adelaide, Australia

Received 1 September 2009 ,Accepted 4 October 2009.

References 

  1. Anderegg TR, Sader HS, Fritsche TR, Ross JE, Jones RN. Trends in linezolid susceptibility patterns: report from the 2002–2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. Int. J. Antimicrob. Agents. 2005;26:13–21
  2. Auckland C, Teare L, Cooke F, Kaufmann ME, Warner M, Jones G, et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 2002;50:743–746
  3. Ballow CH, Biedenbach DJ, Rossi F, Jones RN. Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: report of the Zyvox® Antimicrobial Potency Study in Latin America (LA-ZAPS). Braz. J. Infect. Dis. 2002;6:100–109
  4. Ballow CH, Jones RN, Biedenbach DJ. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn. Microbiol. Infect Dis. 2002;43:75–83
  5. Bell JM, Turnidge JD, Ballow CH, Jones RN. Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific. J. Antimicrob. Chemother. 2003;51:339–345
  6. Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ, Jones RN. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox antimicrobial potency study (ZAPS-Europe). Clin. Microbiol. Infect. 2002;8:791–800
  7. Brickner SJ, Hutchinson DK, Barbachyn MR, Manninen PR, Ulanowicz DA, Garmon SA, et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections. J. Med. Chem. 1996;39:673–679
  8. Clinical and Laboratory Standards Institute . Performance standards for antimicrobial disk susceptibility tests; approved standard - tenth edition, M02-A10. Wayne, PA: CLSI; 2009;
  9. Clinical and Laboratory Standards Institute . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eight edition, M07-A8. Wayne, PA: CLSI; 2009;
  10. Clinical and Laboratory Standards Institute . Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19). Wayne, PA: CLSI; 2009;
  11. Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet. 2001;358:1975–1982
  12. French G. Safety and tolerability of linezolid. J. Antimicrob. Chemother. 2003;51(Suppl 2):ii45–ii53
  13. Gales AC, Sader HS, Andrade SS, Lutz L, Machado A, Barth AL. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis. Int. J. Antimicrob. Agents. 2006;27:300–302
  14. Gemmell CG. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J. Antimicrob. Chemother. 2001;48:47–52
  15. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet. 2001;357:1179
  16. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A. Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group. J. Antimicrob. Chemother. 2000;46:931–940
  17. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. 2002;346:867–869
  18. Jones RN, Johnson DM, Erwin ME. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob. Agents Chemother. 1996;40:720–726
  19. Jones RN, Ballow CH, Biedenbach DJ. Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby–Bauer disk diffusion method: report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. Diagn. Microbiol. Infect. Dis. 2001;40:59–66
  20. Jones RN, Della-Latta P, Lee LV, Biedenbach DJ. Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect Dis. 2002;42:137–139
  21. Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J. Antimicrob. Chemother. 2006;57:279–287
  22. Jones RN, Fritsche TR, Sader HS, Ross JE. Zyvox® Annual Appraisal of Potency and Spectrum Program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn. Microbiol. Infect Dis. 2007;59:199–209
  23. Jones RN, Stilwell MG, Hogan PA, Sheehan DJ. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 2007;51:1491–1493
  24. Jones RN, Ross JE, Castanheira M, Mendes RE. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn. Microbiol. Infect. Dis. 2008;62:416–426
  25. Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis. 2009;64:191–201
  26. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 2004;30:388–394
  27. Marshall SH, Donskey CJ, Hutton-Thomas R, Salata RA, Rice LB. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 2002;46:3334–3336
  28. McCollum M, Sorensen SV, Liu LZ. A comparison of costs and hospital length of stay associated with intravenous/oral linezolid or intravenous vancomycin treatment of complicated skin and soft-tissue infections caused by suspected or confirmed methicillin-resistant Staphylococcus aureus in elderly US patients. Clin. Ther. 2007;29:469–477
  29. McKinnon PS, Carter CT, Girase PG, Liu LZ, Carmeli Y. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective. Manag. Care Interface. 2007;20:23–34
  30. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin. Infect. Dis. 2004;39:1010–1015
  31. Mendes RE, Deshpande LM, Castanheira M, DiPersio J, Saubolle MA, Jones RN. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 2008;52:2244–2246
  32. Moellering RC. Linezolid: the first oxazolidinone antimicrobial. Ann. Intern. Med. 2003;138:135–142
  33. Mouton JW, Jansz AR. The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands. Clin. Microbiol. Infect. 2001;7:486–491
  34. Mutnick AH, Biedenbach DJ, Turnidge JD, Jones RN. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998–2000. Diagn. Microbiol. Infect. Dis. 2002;43:65–73
  35. Mutnick AH, Enne V, Jones RN. Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. Ann. Pharmacother. 2003;37:769–774
  36. Pai MP, Rodvold KA, Schreckenberger PC, Gonzales RD, Petrolatti JM, Quinn JP. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 2002;35:1269–1272
  37. Pogue JM, Paterson DL, Pasculle AW, Potoski BA. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus. Infect. Contr. Hosp. Epidemiol. 2007;28:1382–1388
  38. Poppe S, Schaadt R, Sheehan D, Sahm D, Zurenko G, Shinabarger D. Mutation analysis of Staphylococcus aureus isolates demonstrating trailing linezolid (LZD) endpoints in microdilution MIC assays Abstr. A-088. 106th. Orlando, FL: American Society for Microbiology; 2006;
  39. Rahim S, Pillai SK, Gold HS, Venkataraman L, Inglima K, Press RA. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin. Infect. Dis. 2003;36:E146–E148
  40. Ross JE, Anderegg TR, Sader HS, Fritsche TR, Jones RN. Trends in linezolid susceptibility patterns in 2002: report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. Diagn. Microbiol. Infect. Dis. 2005;52:53–58
  41. Ross JE, Fritsche TR, Sader HS, Jones RN. Oxazolidinone susceptibility patterns for 2005: international report from the Zyvox® Annual Appraisal of Potency and Spectrum Study. Int. J. Antimicrob. Agents. 2007;29:295–301
  42. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. 2001;32:402–412
  43. Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob. Agents Chemother. 2003;47:1824–1831
  44. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J. Antimicrob. Chemother. 2005;56:923–929
  45. Souli M, Sakka V, Galani I, Antoniadou A, Galani L, Siafakas N, et al. Colonisation with vancomycin- and linezolid-resistant Enterococcus faecium in a university hospital: molecular epidemiology and risk factor analysis. Int. J. Antimicrob. Agents. 2009;33:137–142
  46. Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J. Antimicrob. Chemother. 2004;54:832–835
  47. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 2002;34:1481–1490
  48. Tenover FC, Williams PP, Stocker S, Thompson A, Clark LA, Limbago B, et al. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J. Clin. Microbiol. 2007;45:2917–2922
  49. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358:207–208
  50. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother. 2005;49:2260–2266
  51. Wolter N, Smith AM, Farrell DJ, Schaffner W, Moore M, Whitney CG, et al. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother. 2005;49:3554–3557
  52. Woodford N, North SE, Ellington MJ. Detecting mutations that confer oxazolidinone resistance in gram-positive bacteria. Methods Mol. Biol. 2007;373:103–114
  53. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. 2003;25:980–992
  54. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124:1789–1797
  55. Zyvox Package Insert A . available at http://www.pfizer.com/products/rx/rx_product_zyvox.jsp2008;Accessed June 2009

☆ These study results were presented in part as poster A-078 at the 109th Annual Meeting of the American Society for Microbiology, May 17-21, 2009. Philadelphia, Pennsylvania USA.

PII: S0732-8893(09)00411-8

doi: 10.1016/j.diagmicrobio.2009.10.001

Diagnostic Microbiology & Infectious Disease
Volume 65, Issue 4 , Pages 404-413 , December 2009

Article Tools

* Image Usage & Resolution